U.S. markets open in 8 hours 19 minutes
  • S&P Futures

    4,125.75
    +18.75 (+0.46%)
     
  • Dow Futures

    34,071.00
    +133.00 (+0.39%)
     
  • Nasdaq Futures

    13,176.00
    +75.75 (+0.58%)
     
  • Russell 2000 Futures

    2,179.60
    +11.00 (+0.51%)
     
  • Crude Oil

    63.71
    -0.11 (-0.17%)
     
  • Gold

    1,823.50
    -0.50 (-0.03%)
     
  • Silver

    27.08
    +0.02 (+0.06%)
     
  • EUR/USD

    1.2089
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.6680
    0.0000 (0.00%)
     
  • Vix

    23.13
    -4.46 (-16.17%)
     
  • GBP/USD

    1.4045
    -0.0007 (-0.05%)
     
  • USD/JPY

    109.5230
    +0.0890 (+0.08%)
     
  • BTC-USD

    49,267.43
    -1,562.46 (-3.07%)
     
  • CMC Crypto 200

    1,354.55
    -33.35 (-2.40%)
     
  • FTSE 100

    6,963.33
    -41.30 (-0.59%)
     
  • Nikkei 225

    28,073.92
    +625.91 (+2.28%)
     

Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The company's presentation will be available for on-demand viewing beginning on Tuesday, March 9, 2021 at 7:00 a.m. ET and will remain available on the Investors page under Webcasts of Palatin's website: www.Palatin.com for approximately 30 days following the presentation.

Palatin Technologies, Inc.
Palatin Technologies, Inc.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Palatin's products, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, actions by patent offices in the United States and other countries, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-to-participate-in-hc-wainwright-global-life-sciences-virtual-conference-301241305.html

SOURCE Palatin Technologies, Inc.